PD-L1 Specific [68Ga]-Nb-1 Nanobody Probe for PET Imaging in Solid Tumors - Trial NCT06383598
Access comprehensive clinical trial information for NCT06383598 through Pure Global AI's free database. This phase not specified trial is sponsored by Peking University Cancer Hospital & Institute and is currently Recruiting. The study focuses on Solid Tumor. Target enrollment is 50 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Peking University Cancer Hospital & Institute
Timeline & Enrollment
N/A
May 09, 2024
Dec 01, 2026
Primary Outcome
Standardized uptake value๏ผSUV๏ผ
Summary
The objective of the study is to constrcut a noninvasive approach 68Ga-Nb-1 PET/CT to detect
 the PD-L1 expression of tumor lesions in patients with solid tumors and to identify patients
 benefiting from anti-PD-L1 treatment.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06383598
Non-Device Trial